Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Corvus Pharmaceuticals (CRVS) Income towards Parent Company (2022 - 2025)

Corvus Pharmaceuticals has reported Income towards Parent Company over the past 4 years, most recently at -$11.6 million for Q4 2025.

  • Quarterly results put Income towards Parent Company at -$11.6 million for Q4 2025, down 16.85% from a year ago — trailing twelve months through Dec 2025 was -$13.3 million (up 77.45% YoY), and the annual figure for FY2025 was -$13.3 million, up 77.45%.
  • Income towards Parent Company for Q4 2025 was -$11.6 million at Corvus Pharmaceuticals, down from -$9.8 million in the prior quarter.
  • Over the last five years, Income towards Parent Company for CRVS hit a ceiling of $15.7 million in Q1 2025 and a floor of -$39.5 million in Q3 2024.
  • Median Income towards Parent Company over the past 4 years was -$6.6 million (2022), compared with a mean of -$7.9 million.
  • Biggest five-year swings in Income towards Parent Company: plummeted 669.91% in 2024 and later skyrocketed 364.98% in 2025.
  • Corvus Pharmaceuticals' Income towards Parent Company stood at -$5.7 million in 2022, then rose by 7.36% to -$5.2 million in 2023, then crashed by 89.35% to -$9.9 million in 2024, then decreased by 16.85% to -$11.6 million in 2025.
  • The last three reported values for Income towards Parent Company were -$11.6 million (Q4 2025), -$9.8 million (Q3 2025), and -$7.6 million (Q2 2025) per Business Quant data.